WO2005102306A1 - Patch adhésif analgésique anti inflammatoire - Google Patents

Patch adhésif analgésique anti inflammatoire Download PDF

Info

Publication number
WO2005102306A1
WO2005102306A1 PCT/JP2005/007590 JP2005007590W WO2005102306A1 WO 2005102306 A1 WO2005102306 A1 WO 2005102306A1 JP 2005007590 W JP2005007590 W JP 2005007590W WO 2005102306 A1 WO2005102306 A1 WO 2005102306A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
patch
room temperature
solid
diclofenac sodium
Prior art date
Application number
PCT/JP2005/007590
Other languages
English (en)
Japanese (ja)
Inventor
Koji Tanaka
Yasunori Takada
Miyuki Shinmura
Eiji Hashimoto
Original Assignee
Hisamitsu Pharmaceutical Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co., Inc. filed Critical Hisamitsu Pharmaceutical Co., Inc.
Priority to JP2006512579A priority Critical patent/JP4764337B2/ja
Publication of WO2005102306A1 publication Critical patent/WO2005102306A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins

Definitions

  • the present invention relates to a transdermal patch containing an anti-inflammatory analgesic, excellent in stability and transdermal absorption, and less irritating to the skin. More specifically, the present invention relates to a rubber-based pressure-sensitive anti-inflammatory analgesic patch comprising sodium diclofenac, an organic acid which is solid at room temperature, and crotamiton.
  • Sodium diclofenac [(2,6-dichlorophenyl) amino] benzeneacetic acid monosodium salt) was obtained in 1965 by Salimann et al. Of Ciba-Geigy, Switzerland. It is a non-steroidal anti-inflammatory drug that has been newly developed.It is effective for internal use in diseases such as rheumatoid arthritis and osteoarthritis, analgesia and antipyretic effects, and 0.1% eye drops prevent postoperative inflammation. It is applied to stop and so on. On the other hand, recently developed topical 1% gel is used for osteoarthritis and muscle pain. Dosage is 75-LOOmg daily as diclofenac sodium for internal use.
  • Diclofenac sodium is an excellent non-steroidal anti-inflammatory drug, an analgesic. When administered orally, diclofenac sodium is used as an active ingredient because it has side effects such as gastrointestinal disorders. Various topical external preparations have been developed. Recently, in Japan, diclofenac sodium-containing tape preparations have been approved as pharmaceuticals, and overseas, diclofenac sodium cataplasms, diclofenac getylamine salt cataplasms and patches have been proposed.
  • diclofenac sodium is hardly soluble in ether, it is relatively soluble in water and has insufficient transdermal absorbability, and various measures have been taken.
  • an anti-inflammatory analgesic patch with improved solubility and percutaneous absorption of diclofenac sodium which is formed by laminating a pressure-sensitive adhesive layer containing diclofenac sodium and an organic acid on a flexible support (Patent Document 1), which contain non-steroidal anti-inflammatory drug salt compounds, organic acids, and glycos, and have high solubility in the base component and high keratin permeability.
  • diclofenac sodium diclofenac sodium, crotamiton, and dissolution aids for fatty acids that are liquid at room temperature and have 6 to 18 carbon atoms, such as 2-ethylheptanoic acid, pelargonic acid, caprylic acid, oleic acid, and linoleic acid.
  • Diclofenac sodium-containing patch see Patent Document 3
  • diclofenac sodium polycarboxylic acid polyalkyl ester, medium-chain fatty acid triglyceride or crotamiton.
  • At least one kind of oil, (iii) fatty acid which is liquid at normal temperature, (iv) hydrophilic surfactant, and (V) diclofenac sodium-containing OZW type emulsion containing water are contained in the plaster of the patch.
  • Diclofenac sodium-containing patch characterized by being dispersed (see Patent Document 4), drug, crotamiton, rubber-based adhesive, fluid It has excellent drug release and sustainability, containing paraffin, a patch with good support feeling, which has a strong support (see Patent Document 5), an anti-inflammatory analgesic, crotamiton, and a styrene-isoprene-styrene block copolymer.
  • Anti-inflammatory analgesic patch characterized by being dispersed (see Patent Document 4), drug, crotamiton, rubber-based adhesive, fluid It has excellent drug release and sustainability, containing paraffin, a patch with good support feeling, which has a strong support (see Patent Document 5), an anti-
  • organic acids examples include oleic acid, linoleic acid, linolenic acid, isostearic acid, myristic acid, lactic acid, citric acid, oxalic acid, and acetic acid.
  • oleic acid examples include oleic acid, linoleic acid, linolenic acid, isostearic acid, myristic acid, lactic acid, citric acid, oxalic acid, and acetic acid.
  • Patent Document 1 JP-A-61-280426
  • Patent Document 2 JP-A-62-181226
  • Patent Document 3 JP-A-7-89853
  • Patent Document 4 JP-A-6-219940
  • Patent Document 5 JP-A-9 291028
  • Patent Document 6 JP-A-4-321624
  • Patent Document 7 JP-A-2002-338462
  • Patent Document 8 JP-A-11 322595
  • the present invention provides an anti-inflammatory analgesic patch which is excellent in percutaneous absorbability and stability, and has low irritation to the skin. It is another object of the present invention to provide an external preparation of diclofenac sodium which has excellent storage stability without precipitating crystals of the active ingredient even when stored for a long time.
  • the present inventors have been conducting various studies to develop an external preparation having excellent efficacy and safety, and it is preferable to use a solid organic acid in order to increase the absorption of diclofenac sodium. I have found that. However, when a solid organic acid was used, it was found that an organic acid having poor stability over time of the drug product was precipitated, and improvement to prevent such precipitation was required. Therefore, the inventors of the present invention have studied methods for preventing strong precipitation of various solvents, and have found that crotamiton has an excellent precipitation-preventing action.
  • such formulations have significantly reduced skin irritation compared to the prior art of (crotamiton + polyhydric alcohol) absorption enhancing compositions, and diclofenac sodium and organic acids are re-established in the formulation.
  • a base composition and a production method that do not crystallize and have high transdermal absorption of diclofenac sodium have been found.
  • the present invention relates to an anti-inflammatory analgesic patch comprising a rubber-based pressure-sensitive adhesive, characterized in that the drug layer contains diclofenac sodium, an organic acid which is solid at room temperature, and crotamiton. And more specifically, by mixing and dissolving a solid organic acid and diclofenac sodium at room temperature in crotamiton and kneading the solution with a rubber-based adhesive.
  • the present invention relates to an anti-inflammatory analgesic patch which also contains diclofenac sodium, an organic acid which is solid at room temperature, and crotamiton, and which has a rubbery adhesive strength.
  • the present invention provides a crotamiton with an organic acid and diclofenac sodium which are solid at room temperature. Mixing and dissolving, and kneading the solution with a rubber-based pressure-sensitive adhesive, wherein the drug layer contains sodium diclofenac, a solid organic acid at room temperature, and crotamiton;
  • the present invention relates to a method for producing a patch.
  • the anti-inflammatory analgesic patch of the present invention comprises a support, an adhesive layer containing a drug layer, and a release film.
  • the release film is peeled off, and the adhesive layer containing the drug layer is peeled off. Use by attaching to the skin.
  • the adhesive layer of the patch of the present invention contains at least diclofenac sodium, crotamiton, an organic acid which is solid at room temperature, and a rubber-based adhesive.
  • the pressure-sensitive adhesive layer may form a single layer in which these components are mixed, or may be composed of a layer containing a rubber-based pressure-sensitive adhesive and a drug layer containing a drug.
  • the "solid state" of the organic acid that is solid at room temperature in the present invention means that it is in a solid state at room temperature, and more specifically, the organic acid that is solid at room temperature according to the present invention. It is an organic acid having a melting point of room temperature or higher, usually 30 ° C or higher.
  • Preferred organic acids in solid form at room temperature in the present invention include citric acid, tartaric acid, lactic acid, glycolic acid, succinic acid, maleic acid, fumaric acid, and malic acid. It is an acid.
  • More preferred room temperature solid organic acids of the present invention include one or more selected from group consisting of citric acid, tartaric acid, lactic acid, glycolic acid, and malic acid. , And the like. More preferred room temperature solid organic acids include one or more selected room temperature organic hydroxycarboxylic acids selected from the group consisting of citric acid, tartaric acid, and malic acid. Preferably, specific examples of the organic hydroxycarboxylic acid which is solid at room temperature include citric acid, tartaric acid and the like.
  • the organic acid which is solid at room temperature in the present invention can be added in a large amount as long as it can improve the transdermal absorbability of diclofenac sodium. And the need for large amounts of solvent.
  • the preferred amount is about 0.01 to 10 parts by weight, about 0.1 to 5 parts by weight, or about 0.1 to 1 part by weight, preferably about 1 to 1 part by weight, based on 1 part by weight of diclofenac sodium as an active ingredient. 0.3 to 1 part by weight.
  • the amount of the adhesive layer of the patch of the present invention is 0.0. 5 to: LO weight%, preferably 0.1 to 5 weight%, 0.1 to 2 weight%.
  • diclofenac sodium at room temperature and organic acids solid at room temperature can be almost completely dissolved.
  • a solvent is used. Examples of such a solvent include N-methyl-pyrrolidone, crotamiton, methanol, and the like. Considering the compatibility with the rubber-based pressure-sensitive adhesive in the adhesive patch of the present invention and the stability of the pressure-sensitive adhesive layer, Methylpiperidone and crotamiton are preferred.
  • the amount of crotamiton used in the present invention is not particularly limited as long as the amount of the organic acid crystals can be prevented, but is preferably 1 to 20% by mass, 2 to: L0% by mass, More preferably, it is about 2 to 8% by mass.
  • the rubber-based pressure-sensitive adhesive of the pressure-sensitive adhesive layer of the patch of the present invention is a non-aqueous or anhydrous pressure-sensitive adhesive layer composed of a pressure-sensitive adhesive composition mainly composed of natural or synthetic rubber.
  • the pressure-sensitive adhesive composition contains a natural and / or synthetic rubber, a tackifying resin and a softening agent, and may further contain other additives according to the purpose.
  • the synthetic rubber used for the rubber-based pressure-sensitive adhesive of the pressure-sensitive adhesive layer of the patch of the present invention is polyisoprene, polyisobutylene, polybutadiene, styrene-butadiene-styrene block copolymer, styrene-isoprene-styrene block copolymer, styrene-
  • the butadiene rubber, styrene-isoprene rubber and / or group strength are also selected from one or more types.
  • Preferred rubbers include styrene-isoprene-styrene block copolymer, polyisobutylene and the like.
  • the ratio of natural or Z or synthetic rubber in the whole rubber-based adhesive layer is preferably about 10 to 40% by mass and about 20 to 40% by mass.
  • the tackifying resin used for the rubber-based pressure-sensitive adhesive of the pressure-sensitive adhesive layer of the patch of the present invention is not particularly limited as long as it is generally used, but polyterpene resin, rosin ester resin, hydrogenated rosin ester; Fats, alicyclic saturated hydrocarbon resins, terpene phenol resins, petroleum resins and the like are preferably used. Adhesion occupies the entire rubber-based adhesive composition The ratio of the fat and oil is preferably 10-40% by mass.
  • the softening agent used for the rubber-based pressure-sensitive adhesive of the pressure-sensitive adhesive layer of the patch of the present invention is not particularly limited as long as it is a commonly used one, but liquid paraffin, polybutene, liquid polyisobutylene, animal and vegetable oils and the like are preferably used. .
  • the proportion of the softening agent in the whole rubber-based pressure-sensitive adhesive layer is preferably 20 to 70% by mass and 30 to 70% by mass.
  • the adhesive layer of the patch of the present invention may further contain various additives as necessary.
  • additives include drugs, absorption enhancers, fillers, antioxidants, ultraviolet absorbers, fragrances, dyes, and the like.
  • diclofenac sodium in addition to diclofenac sodium, it can be caloric in expectation of a synergistic therapeutic effect, etc., and it can be used as a hot pepper component (such as capsaicin), a warming agent such as nonyl acid ⁇ -lylamide, a cooling agent such as menthol, Essential oil components and others (plant extracts, tocopherol acetate, etc.) can be exemplified.
  • a hot pepper component such as capsaicin
  • a warming agent such as nonyl acid ⁇ -lylamide
  • a cooling agent such as menthol, Essential oil components and others (plant extracts, tocopherol acetate, etc.)
  • the absorption promoter examples include aliphatic alcohols such as oleyl alcohol, fatty acids such as oleic acid, metal salts of fatty acids such as sodium stearate, and fatty acid esters.
  • the filler examples include silicic anhydride, aluminum silicate and the like.
  • the support of the patch of the present invention includes polyethylene, polypropylene, polybutadiene, ethylene vinyl acetate copolymer, butyl acetate-vinyl chloride copolymer, polyvinyl chloride, polyamide, polyester, nylon, cellulose derivative, A film, a sheet, a sheet-like porous body, a sheet-like foam, a woven fabric, a knitted fabric, a nonwoven fabric, a paper, or a laminate thereof of a synthetic resin such as polyurethane can be used.
  • Stretchable materials such as knitted fabrics are preferred from the viewpoint of securing the adhesiveness of the patch to the skin. Further, those having self-supporting property are preferred in terms of the nodling property of the patch.
  • the thickness of the adhesive layer is 10 to 500 ⁇ m, preferably 30 to 300 ⁇ m.
  • polyester, polypropylene, polyethylene, paper, or a laminate obtained by applying a release treatment (such as silicone coating) to a sheet-like material having a laminate strength is preferably used.
  • the method for producing the patch of the present invention is a force that can be produced according to the usual method for producing a non-aqueous or anhydrous patch. Preferred production methods include crotamiton and solid at room temperature. Each of the organic acid and diclofenac sodium is mixed and dissolved, and the resulting solution is kneaded with a rubber-based pressure-sensitive adhesive prepared by kneading to prepare a composition to be a pressure-sensitive adhesive layer.
  • the product can be manufactured by spreading it on a body by coating or the like, and then bonding a release film. Further, if necessary, the product can be cut into an appropriate size to obtain a product. Further, it can be produced by mixing and dissolving an organic acid and diclofenac sodium in crotamiton.
  • the present invention provides a patch excellent in percutaneous absorption of diclofenac as an active ingredient by mixing diclofenac sodium and an organic acid which is solid at room temperature to a rubber-based pressure-sensitive adhesive.
  • a patch can be obtained which is excellent not only in percutaneous absorption of diclofenac but also in stability over time and is less irritating to the skin. Therefore, the patch of the present invention has excellent transdermal absorption of diclofenac, which is an active ingredient, as well as excellent stability over time, and has excellent anti-inflammatory and analgesic effects with little irritation to the skin. It is intended to provide a practical patch having excellent efficacy, safety and stability.
  • the patch of the present invention can be produced by a simple and stable method of kneading a crotamiton solution containing an active ingredient and an absorption promoter and a rubber-based pressure-sensitive adhesive.
  • FIG. 1 is a graph showing the results of a transdermal absorption test of the patch of the present invention and a comparative patch.
  • the present inventors first examined the solubility of various solvents in diclofenac sodium and a solid organic acid at room temperature, taking tartaric acid as an example of a solid organic acid at room temperature.
  • a solvent having a hydroxyl group is excluded from the selection because it is likely to form an ester with diclofenac sodium during storage, which is unfavorable as a solvent in the preparation of the present invention.
  • N-methyl-2-pyrrolidone and crotamiton could be selected as preferred solvents.
  • the patch (1) of the present invention having the following composition was produced by the following method. First, 1 part of diclofenac sodium was dissolved by heating in 3 parts of crotamiton, while 0.4 part of citrate was dissolved by humidification in 1 part of crotamiton, and both solutions were combined into one solution. Further, cefsol (glycerin fatty acid ester, Nikko Chemicals) was added to this solution and mixed to obtain a uniform solution.
  • Styrene-isoprene-styrene block copolymer SIS
  • polyisobutylene PIB
  • liquid paraffin alicyclic petroleum resin
  • the pressure-sensitive adhesive composition obtained above was applied and spread on a support, covered with a liner, and cut into a suitable size to obtain a patch (1).
  • a comparative patch (1) having the following compositional power was produced according to the method described in Example 2.
  • Example 2 According to the method described in Example 2, a patch (2) of the present invention having the following composition was produced.
  • Liquid paraffin 32.3 Alicyclic petroleum resin 32. 3
  • a comparative patch (2) having the following composition was produced according to the method described in Example 2.
  • Example 2 According to the method described in Example 2, a patch (5) of the present invention having the following composition was produced.
  • the skin on the side of the body of the hairless mouse was removed, fat on the dermis side was carefully removed, and the hair was attached to a flow-through cell in which water at 37 ° C was circulated around the outer periphery so that the dermis side became a receptor tank.
  • the patch was applied to the stratum corneum side, and a phosphate buffer solution was passed through the receptor tank at 1 mL / hr, and the buffer solution was collected every 4 hours. From these samples, the drug concentration was quantified by the HPLC method, and the permeation rate (Flux) at each collection time was calculated by the following equation.
  • Transmission cell Vertical flow-through cell
  • Receptor solution 50 mM phosphate buffer, pH 7.4
  • FIG. 1 shows the results graphically.
  • the horizontal axis indicates time (hour), and the vertical axis indicates transmission amount (
  • the black square (country) indicates the patch (1) (Example 2) of the present invention
  • the black diamond ( ⁇ ) indicates the patch (2) (Example 3) of the present invention
  • the black circle (see) Indicates the patch (3) of the present invention (Example 4)
  • the black triangle mark ()) indicates the comparative patch (1) (Comparative Example 1).
  • the storage stability of the patches obtained in Examples 4 and 5 was evaluated as follows. That is, the patch was stored at 25 ° C and 40 ° C, and a sample was collected one month later. From these samples, the drug concentration was quantified by the HPLC method, and the content before storage was calculated as the initial ratio (%), assuming that the content before storage was 100%, and the content after one month.
  • Example 2 and Comparative Example 2 were applied to the inside of the left and right upper arms of three healthy adult boys, respectively, and peeled 24 hours later. One hour after the exfoliation, the skin condition was observed and scored according to the following criteria. In addition, the ratio of the number of persons who recognized any skin reaction was defined as a positive rate (%).
  • the present invention is used for a transdermal patch containing an anti-inflammatory analgesic, which is excellent in stability and transdermal absorbability and has little irritation to the skin, and is extremely useful in industry.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

[PROBLÈMES] Proposer un patch adhésif analgésique anti-inflammatoire étant excellent en termes de capacité d’absorption et de stabilité percutanée et réduisant l'irritation de la peau. [MOYENS POUR RÉSOUDRE LES PROBLÈMES] Le patch adhésif analgésique anti-inflammatoire comprend un adhésif à base de caoutchouc sensible à la pression et est caractérisé par une couche de médicament qui contient du diclofenac sodique, un acide organique solide à température ambiante, et du crotamiton. Il peut être caractérisé comme étant obtenu par mélange d'un acide organique solide à température ambiante et de diclofenac sodique avec du crotamiton pour dissoudre les ingrédients précédents et par malaxage de la solution avec un adhésif à base de caoutchouc sensible à la pression.
PCT/JP2005/007590 2004-04-23 2005-04-21 Patch adhésif analgésique anti inflammatoire WO2005102306A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006512579A JP4764337B2 (ja) 2004-04-23 2005-04-21 消炎鎮痛貼付剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-128838 2004-04-23
JP2004128838 2004-04-23

Publications (1)

Publication Number Publication Date
WO2005102306A1 true WO2005102306A1 (fr) 2005-11-03

Family

ID=35196718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/007590 WO2005102306A1 (fr) 2004-04-23 2005-04-21 Patch adhésif analgésique anti inflammatoire

Country Status (3)

Country Link
JP (1) JP4764337B2 (fr)
TW (1) TWI379667B (fr)
WO (1) WO2005102306A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069662A1 (fr) * 2005-12-13 2007-06-21 Nitto Denko Corporation Preparation adhesive
EP2491924A1 (fr) * 2009-10-23 2012-08-29 Teikoku Seiyaku Co., Ltd. Diclofénac sodique à base de pâte contenant de l'eau
JP2014520867A (ja) * 2011-07-20 2014-08-25 エピファーマ エスアールエル ジクロフェナクおよびチオコルチコシドを含有する貼付剤
CN109481423A (zh) * 2018-11-20 2019-03-19 中国科学院理化技术研究所 一种双氯芬酸盐透皮贴剂及其制备方法
JP2019508082A (ja) * 2015-12-23 2019-03-28 カール オットー ブラウン ゲーエムベーハー ウント コンパニー コマンディトゲゼルシャフト 包帯

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7174076B2 (ja) * 2019-01-31 2022-11-17 久光製薬株式会社 貼付剤

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62181226A (ja) * 1986-02-05 1987-08-08 Ikeda Mohandou:Kk 消炎鎮痛外用剤
JPH04321624A (ja) * 1991-04-19 1992-11-11 Hisamitsu Pharmaceut Co Inc 消炎鎮痛貼付剤
JPH06128426A (ja) * 1992-10-21 1994-05-10 Asahi Chem Ind Co Ltd ポリオレフィン系樹脂組成物
JPH06219940A (ja) * 1993-01-27 1994-08-09 Shiseido Co Ltd 貼付剤
JPH0789853A (ja) * 1993-09-24 1995-04-04 Shiseido Co Ltd 貼付剤
WO2000064435A1 (fr) * 1999-04-26 2000-11-02 Lead Chemical Co., Ltd Preparations a base d'oxybutynine destinees a etre absorbees par voie percutanee
WO2001095889A1 (fr) * 2000-06-13 2001-12-20 Hisamitsu Pharmaceutical Co., Inc. Platre

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280426A (ja) * 1985-06-04 1986-12-11 Ikeda Mohandou:Kk 消炎鎮痛用貼付剤
JP4181232B2 (ja) * 1997-07-18 2008-11-12 帝國製薬株式会社 ジクロフェナクナトリウム含有油性外用貼付製剤
JP4255994B2 (ja) * 1998-05-15 2009-04-22 リンテック株式会社 経皮吸収型解熱消炎鎮痛貼付剤
JP4865958B2 (ja) * 2001-05-23 2012-02-01 株式会社トクホン 鎮痛抗炎症局所作用型の貼付剤
KR100941909B1 (ko) * 2002-02-19 2010-02-16 히사미쓰 세이야꾸 가부시키가이샤 경피흡수형 부착제

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62181226A (ja) * 1986-02-05 1987-08-08 Ikeda Mohandou:Kk 消炎鎮痛外用剤
JPH04321624A (ja) * 1991-04-19 1992-11-11 Hisamitsu Pharmaceut Co Inc 消炎鎮痛貼付剤
JPH06128426A (ja) * 1992-10-21 1994-05-10 Asahi Chem Ind Co Ltd ポリオレフィン系樹脂組成物
JPH06219940A (ja) * 1993-01-27 1994-08-09 Shiseido Co Ltd 貼付剤
JPH0789853A (ja) * 1993-09-24 1995-04-04 Shiseido Co Ltd 貼付剤
WO2000064435A1 (fr) * 1999-04-26 2000-11-02 Lead Chemical Co., Ltd Preparations a base d'oxybutynine destinees a etre absorbees par voie percutanee
WO2001095889A1 (fr) * 2000-06-13 2001-12-20 Hisamitsu Pharmaceutical Co., Inc. Platre

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069662A1 (fr) * 2005-12-13 2007-06-21 Nitto Denko Corporation Preparation adhesive
EP2491924A1 (fr) * 2009-10-23 2012-08-29 Teikoku Seiyaku Co., Ltd. Diclofénac sodique à base de pâte contenant de l'eau
EP2491924A4 (fr) * 2009-10-23 2013-04-10 Teikoku Seiyaku Kk Diclofénac sodique à base de pâte contenant de l'eau
US9168235B2 (en) 2009-10-23 2015-10-27 Teikoku Seiyaku Co., Ltd. Aqueous patches containing diclofenac sodium
JP2014520867A (ja) * 2011-07-20 2014-08-25 エピファーマ エスアールエル ジクロフェナクおよびチオコルチコシドを含有する貼付剤
JP2019508082A (ja) * 2015-12-23 2019-03-28 カール オットー ブラウン ゲーエムベーハー ウント コンパニー コマンディトゲゼルシャフト 包帯
JP7270378B2 (ja) 2015-12-23 2023-05-10 カーオーベー ゲーエムベーハー 包帯
CN109481423A (zh) * 2018-11-20 2019-03-19 中国科学院理化技术研究所 一种双氯芬酸盐透皮贴剂及其制备方法
CN109481423B (zh) * 2018-11-20 2021-10-22 中国科学院理化技术研究所 一种双氯芬酸盐透皮贴剂及其制备方法

Also Published As

Publication number Publication date
JPWO2005102306A1 (ja) 2008-03-06
TWI379667B (en) 2012-12-21
TW200538087A (en) 2005-12-01
JP4764337B2 (ja) 2011-08-31

Similar Documents

Publication Publication Date Title
JP4865958B2 (ja) 鎮痛抗炎症局所作用型の貼付剤
TWI592170B (zh) Adhesive and its manufacturing method
RU2379029C1 (ru) Трансдермальный пластырь, содержащий разагилин, для лечения или профилактики заболеваний нервной системы и способ его приготовления
JP4181232B2 (ja) ジクロフェナクナトリウム含有油性外用貼付製剤
JP5581080B2 (ja) 外用貼付剤
JP5403948B2 (ja) メマンチン含有経皮吸収製剤
WO2003070228A1 (fr) Platre de type a absorption percutanee
JP4764337B2 (ja) 消炎鎮痛貼付剤
JP2010280634A (ja) 消炎鎮痛貼付剤
WO2016080533A1 (fr) Agent d'absorption percutanée
JP6729584B2 (ja) 経皮吸収型貼付剤
WO2016208729A1 (fr) Patch d'absorption percutanée contenant de la nalfurafine
WO2014068600A1 (fr) Système transdermique stable d'administration de médicaments comprenant du diclofénac
WO2018104772A1 (fr) Préparation de type à absorption percutanée
JP6675589B2 (ja) 経皮吸収型製剤
JP4237293B2 (ja) 経皮吸収型貼付剤
JP6459148B2 (ja) 経皮吸収型製剤
WO2017057541A1 (fr) Préparation d'absorption transdermique
JP6512905B2 (ja) フェンタニル含有貼付剤
US9833417B2 (en) Felbinac-containing external patch
JP6104230B2 (ja) 経皮吸収型製剤
CA2244679C (fr) Preparation contenant du tranilast pour application externe et methode de production de cette preparation
JP2023092097A (ja) 非水系貼付剤およびその製造方法
JP2016216384A (ja) 経皮吸収型製剤
JP2017007994A (ja) 経皮吸収型製剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006512579

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase